{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:40:53Z","timestamp":1788522053844,"version":"build-2803163510"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"5-6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Deployed clinicians have limited resources at their disposal to augment medical decision-making and management. All deploying personnel undergo predeployment medical assessment to evaluate their fitness for deployment. The purpose of predeployment screening is to allow for anticipation of medical needs that may arise which could challenge the available medical resources in an expeditionary environment. Medical standards for deployment are published, identifying disqualifying conditions and medications. A history of latent tuberculosis infection is not disqualifying for deployment. Isoniazid is not specifically mentioned as a disqualifying medication, though it is well known to have the potential of causing drug-induced liver injury. Here, a case of fatal isoniazid-induced drug-induced liver injury in a deployed setting is presented with a review of current latent tuberculosis infection literature. Our goal is for the reader to form their own opinion whether or not isoniazid should be used in the forward environment.<\/jats:p>","DOI":"10.1093\/milmed\/usaa414","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T18:21:07Z","timestamp":1604168467000},"page":"619-622","source":"Crossref","is-referenced-by-count":5,"title":["Fatal Isoniazid Hepatotoxicity in the Deployed Environment"],"prefix":"10.1093","volume":"186","author":[{"given":"Daniel J","family":"Cybulski","sequence":"first","affiliation":[{"name":"Craig Joint Theater Hospital, 455th Expeditionary Medical Group, Bagram, AE 09354, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"White","sequence":"additional","affiliation":[{"name":"Craig Joint Theater Hospital, 455th Expeditionary Medical Group, Bagram, AE 09354, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"2021050313325078000_R1","article-title":"Modification 14 (MOD14) to the United States Central Command (USCENTCOM) Individual Protection and Individual\/Unit Deployment Policy"},{"issue":"(RR-6)","key":"2021050313325078000_R2","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society","volume":"49","year":"2000","journal-title":"MMWR Recomm Rep"},{"issue":"k2738","key":"2021050313325078000_R3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2738","article-title":"Revisiting the timetable of tuberculosis","volume":"362","author":"Behr","year":"2018","journal-title":"BMJ"},{"issue":"(1)","key":"2021050313325078000_R4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"(6)","key":"2021050313325078000_R5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection: a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"issue":"(11)","key":"2021050313325078000_R6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"issue":"(1)","key":"2021050313325078000_R7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"issue":"(6)","key":"2021050313325078000_R8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1164\/arrd.1978.117.6.991","article-title":"Isoniazid related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kipanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"issue":"(23)","key":"2021050313325078000_R9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"(5)","key":"2021050313325078000_R10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","year":"2018","journal-title":"N Engl J Med"},{"key":"2021050313325078000_R11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2021050313325078000_R12","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ajg.2014.131","article-title":"ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury","volume":"109","author":"Chalasani","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2021050313325078000_R13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.gastro.2009.06.006","article-title":"Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure","volume":"137","author":"Lee","year":"2009","journal-title":"Gastroenterology"},{"key":"2021050313325078000_R14","article-title":"Modification 15 (MOD15) to the United States Central Command (USCENTCOM) Individual Protection and Individual\/Unit Deployment Policy"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/619\/37774661\/usaa414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/186\/5-6\/619\/37774661\/usaa414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T13:34:57Z","timestamp":1620048897000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/186\/5-6\/619\/5948052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":14,"journal-issue":{"issue":"5-6","published-online":{"date-parts":[[2021,5,3]]},"published-print":{"date-parts":[[2021,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa414","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,5,1]]}}}